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Abstract  
The demand for novel antimicrobial therapies due to the threat posed by antimicrobial resistance has resulted in a growing interest in the 
protective role of our skin bacteria, and the importance of competition between bacteria on the skin. A survey of the cultivable bacteria on 
human skin was undertaken to identify the capacity of the skin microbiota to produce bacteriocins with activity against skin pathogens. Twenty-
one bacteriocins produced by bacteria isolated from seven sites from each subject exhibited inhibition spectra ranging from broad to narrow 
range, inhibiting many Gram-positive bacteria, including opportunistic skin pathogens such as Propionibacterium acnes (recently renamed 
Cutibacterium acnes), Staphylococcus epidermidis, and methicillin-resistant Staphylococcus aureus (MRSA).  Sequencing indicated that the 
antimicrobial-producing isolates were predominately species/strains of the Staphylococcus genus. Colony mass spectrometry revealed peptide 
masses which do not correspond to known bacteriocins. In an era where antibiotic resistance is of major concern, the inhibitory effect of novel 
bacteriocins from bacteria of skin origin demonstrates the antimicrobial potential that could be harnessed from within the human skin 
microbiota. 
Introduction  
The human skin microbiome is home to hundreds of diverse bacterial species from the four phyla Actinobacteria, Proteobacteria, Firmicutes and 
Bacteriodetes, that act as part of the body’s first line of defence against the external environment (Natsuga, 2014). The commensal microbiota of 
the skin contributes to host health and is thought to play a role in protecting the host against a wide range of infections. One such defence 
mechanism is the production of bacteriocins. Bacteriocins are ribsosomally synthesised, heat-stable antimicrobial peptides that are produced by 
bacteria which can exhibit both broad and narrow range inhibition spectra. Lantibiotics belong to class I bacteriocins which are heavily post-
translationally modified - characterised by the presence of lanthionine/B-methyllanthionine residues (McAuliffe, Ross, & Hill, 2001). 
Bacteriocins may exert a diverse array of functions from colonising peptides which help the producer to become established in a niche, to killing 
peptides for eliminating competitors, or as signalling peptides through interactions with other bacteria and the immune system (Bastos, Ceotto, 
Coelho, & Nascimento, 2009; Dobson, Cotter, Ross, & Hill, 2012; Schauber & Gallo, 2008). The importance of these traits can be seen where 
imbalances in the ratio or composition of skin microbiota has been linked to skin diseases/infections such as psoriasis, atopic dermatitis, acne 
and impetigo (Grice, 2014; Otto, 2009; Yamasaki & Gallo, 2008; Zeeuwen, Kleerebezem, Timmerman, & Schalkwijk, 2013). It has been 
hypothesised that restoration of this natural microbial balance could potentially alleviate or prevent such skin infections and would reduce the 
use of antibiotics to treat such conditions (Sanford & Gallo, 2013). 
Staphylococcus species are dominant bacterial colonisers of the skin and are divided into two main groups on the basis of coagulase activity.  
Coagulase triggers the coagulation of soluble fibrinogen forming insoluble fibrin, resulting in the formation of a clot. Thus, coagulase positive 
staphylococci, for example Staphylococcus aureus (S. aureus) which can reside on the skin surface as a commensal organism, are potentially 
pathogenic and are capable of producing haemolysins and a range of heat stable toxins. Conversely, the skin is also colonised by a diverse array 
of coagulase negative Staphylococcus species which form part of the normal commensal bacteria of the skin. The production of lantibiotics is 
abundant within commensal coagulase negative staphylococci, for example Staphylococcus gallinarum, epidermidis and hominis produce the 
lantibiotics gallidermin, epidermin and hominicin, respectively (Götz et al., 2014). Studies have characterised the human skin microbiome in 
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healthy and diseased states (Grice & Segre, 2011), and while little has been done in screening the human skin specifically for novel bacteriocins, 
there is increasing interest in the human skin microbiome as a source of  competitive strains and novel antimicrobials. This has led to the 
discovery of a novel antibiotic, lugdunin, isolated from a nasal strain of Staphylococcus lugdunensis (Zipperer et al., 2016). Furthermore, the 
application of human skin commensals as sources of protection against S. aureus and skin neoplasia’s (Nakatsuji et al., 2017, 2018), highlight 
the potential of human skin commensals as possible alternate solutions to antibiotics. 
Here we describe one approach targeted specifically at the isolation of coagulase negative staphylococcal skin isolates and investigate their 
inhibitory activity against a range of skin pathogens associated with skin infections such as MRSA, atopic dermatitis and acne vulgaricus, as 
well as the causative agents of mastitis.  
Materials and Methods 
Isolation of antimicrobial producing skin isolates 
Twenty healthy volunteers, 18-65 years of age, 13 females and 7 males, were recruited for this study which was approved by the Cork Clinical 
Research Ethics Committee under Protocol number APC071.  Seven different areas of the body were swabbed, specifically the retro auricular 
crease (behind ear), the axillary vault (underarm), the inguinal crease (groin), the umbilicus (bellybutton), the gluteal crease (between lower back 
and buttocks), the alar crease (side of nose) and the toe web space (between toes). Each swab (Sarstedt swabs Amies, PS, Viscose) was dipped in 
sterile saline before swabbing the body area (Landers, Hoet, & Wittum, 2010) and swabs were stored for no more than 12 hours at 4°C before 
being homogenised in 2 mL of Maximum Recovery Diluent (MRD; Oxoid Ltd., Basingstoke, Hampshire, UK). Tenfold serial dilutions were 
performed in MRD and 100 µL aliquots were spread plated onto Mannitol Salt Agar (MSA; Oxoid Ltd.) and Brain Heart Infusion (BHI) agar 
(Merck, Darmstadt, Germany). All plates were incubated aerobically at 37°C for 48h. After incubation, colonies were counted and colonies of 
different morphology and colour were streaked for purity and grown aerobically in 10 mL of BHI broth (Merck) at 37°C in a shaking incubator 
(311DS Labnet) overnight. 
Detection of antimicrobial activity 
Spot bioassays for antimicrobial production were then carried out on the isolates by spotting 10 µL of the overnight culture onto BHI agar, the 
plates were incubated overnight at 37°C and then overlaid with MRS sloppy Lactobacillus MRS broth, (BD™ Difco™ Trafalgar Scientific Ltd, 
Leicester, United Kingdom, LE3 1UQ) containing 0.75% agar seeded with 0.25% of an overnight culture of Lactobacillus delbrueckii ssp. 
bulgaricus LMG 6901 and grown anaerobically overnight (see Table 1 for optimal growth conditions of bacterial strains used in this study). The 
remaining colonies on BHI plates were also overlaid with L. delbrueckii ssp. bulgaricus LMG 6901.  The MSA plates were overlaid with sloppy 
(0.75%) BHI agar seeded with an overnight inoculum of either 0.25% Listeria innocua DPC 3572 or 0.25% MRSA DPC 5645. Colonies from 
spot assays and plate overlays that exhibited zones of inhibition were then inoculated into BHI broth, grown overnight at 37°C and stocked in 
20% glycerol at -80°C for further characterisation (Fig. 1).  
Characterisation of antimicrobial activity of skin isolates 
Well diffusion assays (WDA) 
Cell free supernatants (CFS) were prepared from 10 mL overnight cultures of putative antimicrobial producing strains (isolated from BHI and 
MSA plates) by centrifugation (in Sorvall Legend RT) at 4000xg for 20 minutes following overnight growth in BHI broth in a shaking incubator 
at 37°C (Ryan, Rea, Hill, & Ross, 1996). To eliminate inhibition due to acid, the CFS were neutralised to pH 6.9-7.2 using 1M NaOH. Wells 
were bored in MRS agar plates, previously seeded with 0.25 % inoculum of an overnight culture of L. delbrueckii ssp. bulgaricus LMG 6901, 
and 50 µL of each neutralised supernatant was added to the wells. The plates were incubated anaerobically at 37°C overnight and observed for 
zones of inhibition around the well (Ryan et al. 1996). Strains showing zones of inhibition were selected for further study. 
16S rRNA sequencing  
Genomic DNA was extracted from the antimicrobial producing strains (grown overnight in 10ml BHI broth at 37°C) using Sigma Aldrich DNA 
purification kit as described by the manufacturer (Sigma-Aldrich Ireland Limited, Vale Road, Arklow, Co. Wicklow, Ireland). For 16S rRNA 
sequencing, universal primers Uni F 5’-AGAGTTTGATCCTGGCTCAGG-3’ and Uni R 5’-ACGGCAACCTTGTTACGAGT-3’ were used for 
PCR reactions (run conditions: initial denaturation: 94°C x 5 minutes, cycling conditions: 30 cycles of 94°C x 40 seconds, 55°C x 30 seconds, 
72°C x 1 minute, final extension: 72°C x 10 minutes) to initially identify the antimicrobial producing strains. To confirm species, degenerate 
primers targeting the dnaJ gene (Shah et al., 2007) forward primer: 5’-GCCAAAAGAGACTATTATGA-3’ and reverse primer: 5’-
ATTGYTTACCYGTTTGTGTACC-3’) were used for the PCR reactions following conditions described by Shah et al., (2007). Quantification 
of the extracted DNA and PCR products was conducted using Qubit 2.0 fluorometer (Thermo Fisher Scientific, 168 Third Avenue Waltham, 
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MA USA 02451). Sequencing was conducted by Genewiz (Hope End, Takeley, Essex, CM22 6TA, United Kingdom) and analyses of the 
sequencing data were performed utilising Lasergene 8 software (DNAStar Inc., Madison, WI). Basic local alignment search tool (BLAST) on 
the National Centre for Biotechnology Information (NCBI) server (http://www.ncbi.nlm.nih.gov) was used to compare the sequencing data of 
the isolates to existing genomic data.  
Heat stability and protease sensitivity  
To establish the heat stability of bacteriocins produced, CFS were incubated for 10 minutes at a range of temperatures: 37°C, 60°C, 70°C, 80°C, 
90°C, 100°C and for 15 minutes at 121°C before performing a WDA in 1.5% MRS agar seeded with 0.25% L. delbrueckii ssp. bulgaricus LMG 
6901 as previously described, see supplementary information figure S2 A. 
To investigate whether the antimicrobials produced were proteinaceous in nature, the CFS of all antimicrobial producing isolates were incubated 
with Proteinase K (Sigma) to a final concentration of 20 mg/mL at 37°C for 1 hour and tested for antimicrobial activity by WDA using L. 
delbrueckii ssp. bulgaricus LMG 6901 as the target organism as described above. The corresponding CFS, mixed with an equivalent volume of 
water, was used as a control, see supplementary information figure S2 B and C. 
Cross Immunity 
To determine the relatedness of the bacteriocins produced by the strains, cross immunity assays were performed as follows: CFS of all producing  
strains were tested against each other  by conducting WDA assays as  previously described using each producing strain as a producer and also as 
a  target strain. Each producing strain was inoculated individually (at 0.25%) into BHI agar which was allowed to solidify and 50 µL of the pH 
neutralised CFS of each strain was added to wells of all plates.  
Spectrum of Inhibition 
A spectrum of inhibition was completed on pH adjusted CFS of all antimicrobial producing isolates using 28 indicator strains by WDA as 
described previously. The target strains, media and incubation temperatures are outlined in Table 1. All indicator strains were diluted to the same 
optical density, (OD600 nm 0.8), using Biochrom Libra S2 Collimeter (Biochrom Ltd., Cambourne Business Park, Cambridge, United Kingdom, 
CB23 6DW) before seeding the agar. Indicator strains employed to detect antimicrobial activity and their optimal growth conditions are listed in 
Table 1. Zone size was measured as follows: area of zone πr
2
 - area of well πr
2
in millimetres. 
Pulsed Field Gel Electrophoresis 
All isolates identified as Staphylococcus species were finger printed using Pulsed Field Gel Electrophoresis (PFGE) as described by Bannerman 
et al. with minor modifications (Bannerman et al., 1995). Cultures were inoculated at 0.02% and grown in a shaking incubator overnight in 5 mL 
BHI broth at 37
o
C. The overnight culture (0.7 mL) was centrifuged for 2 minutes at 4500xg in an Eppendorf Centrifuge. The supernatant was 
discarded, and the cell pellets were washed in 1 mL of sterile TE buffer (0.1 M Tris Cl, 0.15 M NaCl, 0.1M EDTA pH7.5) and recentrifuged. 
Washed cells were resuspended in 0.3 mL of sterile EC buffer (6 mM Tris-HCl, 1 M NaCl, 0.1 M EDTA, 1% Sarkosyl). A solution of 
lysostaphin (1 mg/mL) was prepared in 20 mM sodium acetate (pH4.5) and 2 µL was added to the cell suspension and then vortexed. A 2% Sea 
Plaque agarose (Bio-Rad Laboratories Ltd., Watford, Hertfordshire United Kingdom, WD17 1ET) solution was prepared in EC buffer and 300 
µL added to 300 µL lysostaphin-cell suspension mixed gently to  avoid the formation of bubbles and then quickly pipetted into PFGE plug 
molds. The agar plugs were allowed to solidify at room temperature for 10 minutes.  When solidified, the plugs were incubated in 3 mL EC 
buffer overnight at 37°C. After overnight incubation, the EC buffer was removed and replaced with 3 mL TE buffer (10 mM Tris Cl, 1 mM 
EDTA) and incubated for 1 hour at 55°C without shaking. Prior to electrophoresis, the plugs were cut into small slices 2x5 mm and transferred 
into Eppendorf tubes containing 125 µL of 20U SmaI restriction enzyme (New England Biolabs, 75-77 Knowl Piece, Wilbury Way, Hitchin, 
Herts, United Kingdom, SG4 0TY) in buffer. Plugs were incubated shaking overnight (300 rpm) at 25°C. Following digestion, trimmed slices of 
plug were loaded onto the PFGE comb, fixed with 1% PFGE grade agarose (Bio-Rad Laboratories) in 0.5X Tris-borate EDTA (TBE) buffer. 
Lambda PFGE marker (New England Biolabs) was loaded onto the gel as described above and used as reference ladder.  The gel was run in 
0.5X TBE buffer using a CHEF-DR II®PFGE apparatus using the following gel running parameters: initial pulse: 5 seconds, final pulse 40 
seconds, voltage 200 V or 6 V/cm  for  20 hours at 12°C-14°C. The gel was stained for 2 hours with Ethidium bromide (0.5 µg/mL), destained 
for 1 hour in distilled water and then photographed using GelDoc-It Imager (Ultra-Violet Products Ltd., Cambridge, UK).  
Activity Units 
For the 13 different antimicrobial producing strains identified from PFGE, bacteriocin activity units (AU) were calculated as described by Nilsen 
et al. 2002 based on the WDA. Briefly, 50 µL of CFS was diluted 2 fold and dilutions were dispensed into wells of plates seeded with indicators 
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listed in Table 4. AU were calculated by multiplying the reciprocal of the lowest dilution of the CFS, which produced zones of inhibition by 20 
in order to obtain AU/mL, see Table 4. This assay was performed in duplicate. 
MALDI TOF Mass Spectrometry  
Colonies from the 13 antimicrobial producing skin isolates were mixed with 50 µL propan-2-ol 0.1% TFA, vortexed three times and centrifuged 
at 16000xg for 30 seconds. MALDI TOF mass spectrometry was performed on the CFS using an Axima TOF
2
 MALDI TOF mass spectrometer 
(Shimadzu Biotech, Manchester, UK). An aliquot (0.5 µL) of matrix solution (α-cyano 4-hydroxy cinnamic acid, 10 mg ml-1 in acetonitrile-0.1% 
(v/v) trifluoroacetic acid) was deposited onto the target and left for 10 seconds before being removed. The residual solution was allowed to air-
dry and 0.5 µL of sample solution was deposited onto the pre-coated sample spot; 0.5 µL of matrix solution was added to the deposited sample 
and allowed to air-dry. The sample was then analysed in positive-ion linear mode and peptide masses compared to the bacteriocin database, 
‘Bactibase’ to identify putative bacteriocins. 
Results and Discussion 
The human skin microbiome is home to trillions of bacteria but is predominately colonised by members of the genus Staphylococcus (Otto, 
2010). The skin is the defensive barrier that separates our internal organs from the external world. It acts as a first line of defence against 
pathogens, and the layers of skin help prevent harmful substances from accessing the body (Sanford & Gallo, 2013; Zeeuwen, Kleerebezem, 
Timmerman, & Schalkwijk, 2013). Significant therapeutic potential has been identified for the staphylococcal genus, including the production of 
class 1a lantibiotics such as epidermin, nukacin, gallidermin and aureocin (Netz et al., 2002; Sashihara et al., 2000; Schnell et al., 1989, 1992), as 
well as a novel antibiotic lugdenin (Zipperer et al., 2016). Consequently, a culture-based approach was adopted in this study to isolate 
antimicrobial-producing bacteria with a particular focus on those that exhibit inhibitory activity against bacteria involved in the pathogenesis of 
skin infections. These include MRSA, Staphylococcus epidermidis, Cutibacterium acnes and a number of mastitic pathogens, such as 
Streptococcus uberis (St. uberis), St. bovis, St. agalactiae, St. dysgalactiae and S. aureus. 
Detection and isolation of antimicrobial producing skin isolates 
Twenty volunteers of mixed age, gender and race were recruited to provide swabs from seven body locations. The body sites were chosen based 
on the varied bacterial compositions of different skin areas (Grice & Segre, 2011). Superficial swabs were employed in this study because the 
swabbing method was less invasive, and was reported to yield a largely similar microbiota profile to that associated with skin scraping of 
epidermis or punch biopsy of the full thickness of epidermis and dermis when next generation sequencing methods were used (Grice et al., 
2008). Over 90,000 colonies were initially screened for antimicrobial activity; these were isolated from 7 sites from 20 individuals (140 sites) 
using the agar overlay technique on the original isolation plates. Samples were serially diluted and spread plated onto the surface of BHI and 
MSA agar plates and all plates which contained visible growth were counted as potential antimicrobial producers, and overlaid with L. 
delbrueckii ssp. bulgaricus or MRSA / L. innocua respectively. At this stage of the study the genetic relationship between the colonies was not 
determined. Spot bioassays on selected individual colonies and original plate overlays identified 101 possible antimicrobial producing isolates 
(see supplementary information for more details). To confirm that an antimicrobial substance was secreted into the growth medium, neutralised 
CFS was tested against L. delbrueckii ssp. bulgaricus LMG 6901 by WDA and this reduced the number of possible bacteriocin producers to 25, 
giving an observed frequency of 0.03% from the 90,000 colonies screened in this study. Due to small zone sizes four of the antimicrobial 
producers were discarded. L. delbrueckii ssp. bulgaricus LMG 6901 was selected as the primary indicator for all assays, due to its insensitivity to 
acid thus reducing the frequency of false positives (Casey et al., 2004). While it is now accepted that many bacteria in natural ecosystems have 
the genetic potential to produce bacteriocin-like inhibitors, their detection in vitro is largely dependent on the screening methods undertaken. The 
low frequency observed in this study may be contributed to the fact that only L. delbrueckii ssp. bulgaricus was used as the primary indicator 
bacteria. 
 Identification of antimicrobial producing skin isolates 
16SrRNA sequencing of the 25 antimicrobial producing isolates revealed four were Bacillus species - Bacillus licheniformis (2), Bacillus 
endophyticus and Bacillus safensis - but the remainder were coagulase negative Staphylococcus species. However, further analysis by 
amplification of the DnaJ gene was required to further differentiate between Staphylococcus species. Five Staphylococcus species were 
identified, including S. capitis (9), S. hominis (4), S. epidermidis (1), S. simulans (1), and S. warneri (6) (Table 2). S. capitis, a frequent coloniser 
of human skin, was the most prevalent species isolated (43%) followed by S. warneri (29%), which has been reported to be a less frequent skin 
coloniser (Otto, 2010) (Otto, 2011). Twelve strains (~50%) of antimicrobial producing staphylococci were isolated from the toe web-space body 
area. The four antimicrobials omitted from study as they were considered poor producers were Bacillus species. 
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Characterisation of antimicrobial producing skin isolates 
A characteristic of bacteriocins is that they are relatively heat stable and are susceptible to degradation by proteolytic enzymes (Jack, Tagg, & 
Ray, 1995). Antimicrobial activity in the CFS from all strains was eliminated following proteinase K treatment indicating that the antimicrobials 
were proteinaceous in nature (see supplementary information fig. S2). In addition, all antimicrobials were stable up to 100 °C for 10 minutes and 
showed only a 50% reduction in activity after autoclaving at 121 °C for 15 minutes (see supplementary information fig. S2).  
One of the features of bacteriocin production is that the genome of producers must harbour immunity gene(s) which protect producers from the 
antimicrobial effects of the bacteriocin they produce (Cotter, Hill, & Ross, 2005; Yang, Lin, Sung, & Fang, 2014).  Cross immunity assays were 
performed to determine if the producing strains were sensitive to the antimicrobial activity of the other producers (Fig. 2). To determine the 
genetic relatedness of the 21 staphylococci isolated, the strains were fingerprinted using PFGE and similarities were categorised based on the 
procedure described by Tenover et al., (1995). Strains of the same species are closely related, in some cases only differing from each other by a 
single DNA band for example S. hominis strains APC 2925, APC 2924 and S. capitis strains APC 2934 and APC 2918 (Fig. 3).  However, the 
PFGE analysis revealed 13 genetically different antimicrobial producing staphylococci - three S. hominis, four S. warneri, one S. epidermidis, 
one S. simulans and four S. capitis. 
Combining data from cross immunity assays and PFGE analysis revealed that antimicrobials produced by skin isolates of the same species and 
of the same or similar pulsotype were immune to each other; suggesting they are the same strain and are most likely producing the same 
bacteriocin. For example, two S. hominis strains APC 2925 and APC 2939, isolated from different body areas (toe web-space and gluteal crease) 
of the same subject, yielded the same pulsotype (lanes 1 and 3 on PFGE gel), had the same immunity pattern as another S. hominis strain, APC 
2924, from a different subject whose pulsotype differed by just one SmaI digestion DNA band (lane 2 on PFGE gel). This was also the case for 
two S. capitis strains from two different subjects (APC 2934 and APC 2918, lanes 13 and 14 of PFGE gel). This shows that some different 
strains which are closely related can produce the same bacteriocin.  
PFGE profiles demonstrated that the same pulsotype can be shared across a number of individuals, with the same S. capitis pulsotype isolated 
from four different subjects (Fig. 3, lanes 15- 19) and three subjects sharing the same S. warneri pulsotype; APC 2942, APC 2937 and APC 2940 
(Fig. 3, lanes 5, 7 and 9). Interestingly, we also showed that the same subject can carry more than one strain of the same species; S. warneri APC 
2947 and APC 2940 were isolated from subject seven. These strains were isolated from different locations on the body and exhibited different 
pulsotypes – (Fig. 3, lanes 8 and 9). S. warneri APC 2947 had a very different pulsotype to other S. warneri strains isolated in this study and 
while it was immune to the bacteriocin produced by others of the same species, it had a different immunity pattern in that it was inhibited by S. 
capitis skin isolates unlike other S. warneri (Fig. 2; Fig 3, lane 8). 
Bacteriocins such as thuricin and nisin have either a narrow or broad spectrum of activity, respectively (Rea et al., 2010; Shin et al., 2016), and 
both of these characteristics may be of benefit to the producing strain depending on the niche inhabited by the bacterium. In a crowded 
environment like the skin, bacteriocin production might help producing strains establish themselves in a particular skin environment. For 
example, the production of narrow spectrum bacteriocins may confer a competitive advantage to strains, allowing them to inhibit closely related 
species that would be competing for similar nutrients on the skin (Dobson, Cotter, Ross, & Hill, 2012). Table 3 shows the spectrum of inhibition 
of the bacteriocins produced against a panel of bacteria including skin pathogens such as Cutibacterium acnes, S. epidermidis, Corynebacterium 
xerosis and MRSA. The majority of S. warneri exhibited the broadest spectrum of activity, inhibiting nine of the indicator strains; while the 
inhibitory activity of three strains (APC 2930, APC 3477 and APC 2926) was shown to exhibit a narrow inhibition spectrum - inhibiting only the 
primary indicator L. delbrueckii ssp. bulgaricus. 
While the majority of our commensal or resident skin microbiota are beneficial to skin health, occasionally the microbes that inhabit our skin can 
develop into opportunistic pathogens, for example S. lugdunensis and S. capitis (Bӧcher, Tønning, Skov, & Prag, 2009; Cameron et al., 2015). 
Even the most abundant species of Staphylococcus on human skin, S. epidermidis, can become pathogenic if the conditions are suitable (Cogen, 
Nizet, & Gallo, 2008). Disruptions to the microbial composition of the skin are responsible for skin conditions such as psoriasis, atopic 
dermatitis, impetigo and acne, and sometimes these imbalances can also prevent healing of chronic wounds (Grice, 2014). Two S. capitis strains 
(APC 2934 and APC 2918) isolated in this study exhibited inhibitory activity of 160 AU/mL against S. epidermidis (DPC 5990) (Tables 3 and 
4). 
S. aureus in particular is known for developing antibiotic resistance (Chambers & Deleo, 2010). MRSA was first identified in 1960 and since 
then has become one of the most prevalent antibiotic resistant pathogens worldwide and is characterised by swollen red lesions containing pus 
following infection of skin wounds, it also causes many other diseases, including pneumatic diseases that can result in mortality in the elderly. A 
study investigating incidence of MRSA in S. aureus isolates in Prince of Songkhla Hospital, Thailand found that 60.9% of the S. aureus isolates 
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were methicillin resistant (Indrawattana et al., 2013) while a study on skin and soft tissue infections carried out in medical centres in Europe 
revealed that the most prevalent pathogen was MRSA (22.5%) (Johnson, 2011). MRSA is first treated with glycopeptide antibiotics such as 
vancomycin, (Santajit & Indrawattana, 2016). However the development of novel antimicrobial therapies for methicillin resistant and 
vancomycin resistant S. aureus are included in the second highest priority group in a list of priority pathogens published by the WHO in a recent 
report describing antimicrobial resistance as a ‘global emergency’ (http://www.who.int/antimicrobial-resistance/en/). Alternative interventions to 
alleviate the problems posed by MRSA and other antimicrobial resistant pathogens are urgently required. S. capitis strains APC 2934 and APC 
2918 with very similar pulsotypes (Fig 3, lanes 13 and 14) were isolated in this study from two different subjects, from different body areas 
inguinal crease and alar crease, and were immune to each other’s antimicrobial activity (Fig 2). These strains exhibited inhibitory activity, 80 
AU/mL and 40 AU/mL respectively, against a strain of the skin pathogen MRSA (DPC 5645) (Table 3 and 4). 
Many adolescents and adults will experience the effects of acne vulgaricus at some point in their lives (Webster, 2002). Patients suffering from 
mild acne are often prescribed topical antibiotics or antiseptics at the beginning of treatment, such as clindamycin, erythromycin, benzoyl 
peroxide, topical retinoid or a combination of these products. However if these are ineffective, or if the acne is classified as moderate to severe, 
then patients are often prescribed systemic treatments including oral antibiotics including tetracyclines, erythromycin, trimethoprim–
sulfamethoxazole hormone therapy and retinoid-isotreretinoin, often for long periods (Raithi, 2011). According to ‘TIME Health’, acne patients 
stay on antibiotics for four times the recommended time period. Eight skin isolates in this study displayed inhibitory activity of 40 AU/ mL 
against Cutibacterium acnes, which is a leading cause of acne vulgaricus (see Table 3 and 4). Seven of these isolates were S. capitis, however, 
there were three distinct pulsotypes. S. hominis APC 3365 was also active against C. acnes. 
Corynebacterium xerosis is a Gram positive aerobic bacterium, and a commensal of the human skin. C. xerosis can cause bacteremia, skin 
infections, endocarditis and pneumonia in immune-compromised patients (Pessanha, Farb, Lwin, Lloyd, & Virmani, 2003).  Three S. hominis 
and five S. warneri demonstrated inhibitory activity of 40 AU/mL and 80 AU/mL against C. xerosis (Table 3 and 4), and against other 
Corynebacterium species (results not shown). PFGE analysis revealed five distinct pulsotypes (two S. hominis and three S. warneri strains (Fig. 
3)).  In addition to highlighting the therapeutic potential of coagulase negative staphylococci on human skin by inhibiting skin pathogens, we 
also observed the ability of skin commensals to inhibit other pathogens such as Listeria monocytogenes (Table 3, APC 2924, APC 2925, APC 
2939- 2 distinct strains from PFGE, Fig. 3) and Streptococcus species involved in bovine mastitis, such as St. uberis, St. agalactiae and St. 
dysgalactiae (Table 3). While traditionally S. aureus was the most common cause of mastitis in dairy cows, more recently St. uberis has been 
shown to be increasingly associated with infection (Kromker, et al., 2014). In this study, three Staphylococcus species, S. hominis, S. warneri 
and S. capitis inhibited a range of Streptococcus species (St. uberis, St. bovis, St. agalactiae and St. dysgalactiae) which have been implicated in 
bovine mastitis (Table 3) with AU ranging from 20 to 320 AU/mL (Table 4). St. uberis is of particular interest as it has been increasingly shown 
to be one of the causative agents of bovine mastitis in the UK. This shows that the antimicrobial producing human skin isolates may also have 
applications in veterinary medicine for the treatment of mastitis given their ability to inhibit both Staphylococcus and Streptococcus species, and 
could aid in the search for non-antibiotic solutions to mastitis treatment to reduce antibiotics in the food chain. Mastitis in humans is also a major 
health issue (Michie, Lockie, & Lynn, 2003). S. epidermidis and streptococci are among the most prevalent causative agents in this infection, 
found in 87.6% and 68.6% of mastitic human breast milk samples, respectively (Marín, Arroyo, Espinosa-Martos, Fernández, & Rodríguez, 
2017). Bacteriocin producers from human skin, identified in this study, exhibited inhibitory activity against staphylococcal and streptococcal 
species thus highlighting their potential as live bio-therapeutics for the treatment of human mastitis. 
Colony mass spectrometry can be used to identify antimicrobial peptides if they can be matched to known peptide masses in the Bactibase 
database. However, in this case the peptide masses detected did not match any known bacteriocins, suggesting these isolates are potentially 
producing novel bacteriocins. The Maldi-TOF MS profiles of the 13 antimicrobial producing staphylococci are shown in Supplementary figure 
S3. 
Conclusion 
There is a need to identify new antimicrobial strains with the potential to outcompete pathogens in the skin environment. The skin is a protective 
defence shielding us from the external environment (Yamasaki & Gallo, 2008). This study has highlighted that the skin microbiota is home to 
many bacteriocin producing strains which may indicate that the skin microbiota is an important tool in our fight against antimicrobial resistance.  
Indeed, this screening has resulted in the isolation of a set of 13 novel bacteriocin producing human skin isolates with potential to restore 
imbalances of skin microbiota as well as inhibit skin pathogens such as MRSA and Cutibacterium acnes. More importantly, these strains may 
prove useful as probiotics for topical skin applications to provide colonization resistance by replacement of skin pathogens and particularly 
MRSA. Further characterisation studies will be carried out on these bacteriocin- producing skin isolates. 
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Figure 1: A:  Overlay of an original plate containing dilution of a toe swab with L. delbrueckii ssp. bulgaricus DPC 6901. B: Spot assay of 10 µL of 
inoculum from colonies of varying morphology isolated from swab dilution plates, overlaid with L. delbrueckii ssp. bulgaricus DPC 6901. C: Well diffusion 
assay of antimicrobial producing skin isolates in agar seeded with L. delbrueckii ssp. bulgaricus DPC 6901 to confirm positive result in spot assay was due to 
antimicrobial substance secreted into CFS. 
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Figure 2: Cross immunity assays using CFS from all the antimicrobial producing strains tested against themselves and each other with the list of 
antimicrobial producing isolates down the left hand side and the indicator strains across the top of the Table. The diagonal green line  reveals that the 
antimicrobial producer is immune to its own antimicrobial as expected. The red box  represents inhibition of the indicator strain indicating that these strains 
might be different or sensitive to each other. (orange) = small/ medium hazy zones. (yellow) = very small zones but sensitive. White boxes represent no 
inhibition revealing target strains not inhibited by the producing strain, indicating they are immune (related) to the bacteriocins produced by other producers. 
*=initially sensitive but bactostatic activity observed.  
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Figure 3: PFGE macro-digestion patterns of staphylococcal skin isolates following genomic digestion with Sma1. Lanes 1-4= Staphylococcus hominis: APC 
2925, 2924, 2939 and 3365; lanes 5-10= Staphylococcus warneri: APC 2942, 2922, 2937, 2947, 2940 and 2930; lane 11= Staphylococcus epidermidis: APC 
3477; lane 12= Staphylococcus simulans APC 2926; lanes 13-21= Staphylococcus capitis APC 2934, 2918, 2923, 2941, 3480, 2946, 2932, 2927 and 3481.  
Lanes 4, 15 and 22 were taken from other PFGE gels with the same- lambda marker (M) and inputted into this gel. epi = epidermidis ; sim = simulans. 
Artefact in lane 3 below first band is not a SmaI DNA band 
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Table 1: Growth conditions of the indicator strains used in this study. 
Species Strain Growth conditions 
  
Temp 
(°C) 
Atmosphere 
 
Growth media 
 
Bifidobacterium longum subsp. infantis ATCC 15697 37 Anaerobic* mMRS 
Bifidobacterium longum subsp. longum DSM 20097 37 Anaerobic* mMRS 
Corynebacterium xerosis DPC 5629 37 Aerobic BHI 
Corynebacterium variablis NCIMB 702097 30 Aerobic BHI 
Cutibacterium acnes 
 
 LMG 16711 
 
37 
 
 
Anaerobic* 
 
mRCM & 
RCA  
Enterococcus faecalis  ATCC 19433 37 Anaerobic* MRS 
Fusobacterium varium DSM 19868 37 Anaerobic* BHI 
Lactobacillus delbrueckii subsp. 
bulgaricus LMG 6901 37 Anaerobic* MRS 
Lactobacillus  fermentum APC 2582 37 Anaerobic* MRS 
Lactobacillus  rhamnosus APC 3483 37 Anaerobic* MRS 
Listeria innocua DPC 3572 37 Aerobic BHI 
Listeria monocytogenes  DPC 5788 37 Aerobic BHI 
Listeria monocytogenes   DPC 6893 37 Aerobic BHI 
Listeria monocytogenes   NCTC 5348 37 Aerobic BHI 
Pseudomonas aeruginosa NCIMB 8295 37 Aerobic BHI 
Pseudomonas aeruginosa APC 2064 37 Aerobic BHI 
Pseudomonas fluorescens DPC 6056 30 Aerobic BHI 
Pseudomonas putita ATCC 17522 37 Aerobic BHI 
MRSA  DPC 5645 37 Aerobic BHI 
Staphylococcus aureus ATCC 25923 37 Aerobic BHI 
Staphylococcus aureus  DPC 7016 37 Aerobic BHI 
Staphylococcus capitis APC 2923 37 Aerobic BHI 
Staphylococcus  epidermidis DPC 5990 37 Aerobic BHI 
Staphylococcus simulans APC 3482 37 Aerobic BHI 
Streptococcus agalactiae ATCC 13813 37 Aerobic BHI 
Streptococcus bovis DPC 6491 37 Aerobic GM17 
Streptococcus dysgalactiae APC 3484 37 Aerobic BHI 
Streptococcus  uberis DPC 5344 37 Aerobic BHI 
 
mMRS= modified MRS, mRCM= modified Reinforced Clostridium Media (made following ATCC Medium:2107 Modified Reinforced Clostridial Agar/ broth  (pre-
reduced)  protocol), RCA= Reinforced Clostridium Agar.  
*
=Anaerobic conditions, where appropriate, were achieved through the use of anaerobic jars and Anaerocult ® A gas packs (Merck, Darmstadt, Germany). 
ATCC= American Type Culture Collection, APC= APC Microbiome Ireland culture collection, DPC= Teagasc culture collection, WSLC= Weihenstephan Listeria 
Collection, LMG= Laboratorium voor Microbiologie, Universteit Gent, Belgium 
 
Table 2:  Identification of antimicrobial producing strains isolated from skin. 
    Strain Identity 
 
 
Strain number Subject no. Body area PFGE lane 
no. 
Staphylococcus hominis APC 2925  SM019 toe web-space  1
$
 
Staphylococcus hominis APC 2924 SM012 toe  web-space 2 
Staphylococcus hominis APC 2939 SM019 gluteal crease  3
$
 
Staphylococcus hominis APC 3365 SM020 gluteal crease 4 
Staphylococcus warneri APC 2942 SM009 axillary vault  5
*
 
Staphylococcus warneri APC 2922 SM001 toe  web-space 6 
Staphylococcus warneri APC 2937 SM006 gluteal crease  7
*
 
Staphylococcus warneri APC 2947 SM007 toe  web-space 8 
Staphylococcus warneri APC 2940 SM007 gluteal crease  9
*
 
Staphylococcus warneri APC 2930 SM015 toe  web-space 10 
Staphylococcus epidermidis APC 3477 SM015 toe  web-space 11 
Staphylococcus simulans APC 2926 SM002 toe  web-space 12 
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$, *,  ¤, π
 These symbols are used to reflect identical PFGE patterns from Fig. 3. 
 
 
 
 
Table 3: Spectrum of inhibition of bacteriocin producing skin isolates against indicator strains subjected to well diffusion assays. +<50 mm
2
; ++50-150mm
2
; 
+++150-249mm
2
; ++++ 250-349mm
2
; 350-449mm
2
; ++++++>450 (Calculated as area of zone πr
2
 - area of well πr
2
in millimetres). 
 
 Other strains tested against but were not inhibited can be seen on Table 1.  
  
Staphylococcus capitis APC 2934 SM003 inguinal crease  13
 
 
Staphylococcus capitis APC 2918 SM001 alar crease  14
 
 
Staphylococcus capitis APC 2923 SM007 toe  web-space  15
¤
 
Staphylococcus capitis APC 2941 SM010 umbilicus  16
¤
 
Staphylococcus capitis APC 3480 SM009 umbilicus  17
¤
 
Staphylococcus capitis APC 2946 SM008 toe  web-space  18
¤
 
Staphylococcus capitis APC 2932 SM008 toe  web-space 19
¤
 
Staphylococcus capitis APC 2927 SM015 toe  web-space 20
 π
 
Staphylococcus  capitis APC 3481 SM015 toe  web-space 21
 π
 
D
ow
nloaded from
 https://academ
ic.oup.com
/fem
sec/advance-article-abstract/doi/10.1093/fem
sec/fiy241/5259109 by Teagasc user on 07 January 2019
  
Table 4: Activity Units per mL from well diffusion assays of the 13 different bacteriocin producing skin isolates against indicator strain. (S. hominis APC  
2925, 2924, 3365; S. warneri APC 2922, 2937, 2947, 2930; S. epidermidis APC 3477; S. simulans APC 2926; S. capitis APC 2934, 2918, 2923, 2927). 
Indicator strains 
Producer strain 
2925 2924 3365 2922 2937 2947 2930 3477 2926 2934 2918 2923 2927 
                          
               
Corynebacterium 
xerosis 
DPC 
5629 40 40 
 
 - 80 80 80 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
Cutibacterium acnes 
 LMG 
16711 
  
- 
 
 - 40 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 40 40 40 
 
 - 
Lactobacillus 
bulgaricus 
LMG 
6901 80 80 320 640 640 640 160 320 40 80 80 1280 640 
Lactobacillus 
fermentum 
APC 
2582 40 40 20 80 80 80 
 
 - 
 
- 
 
 - 20 20 40 20 
Listeria 
monocytogenes  
DPC 
6893 40 40 
 
- 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
MRSA  
DPC 
5645 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 80 40  - 
 
 - 
Staphylococcus 
aureus 
ATCC 
25923 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 40 40  - 
 
 - 
Staphylococcus 
aureus  
DPC 
7016 
 
 - 
 
 - 
 
 - 80 20 40 
 
 - 
 
 - 
 
 - 40 40  - 
 
 - 
Staphylococcus 
epidermidis 
DPC 
5990 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 160 160  - 
 
 - 
Staphylococcus 
simulans 
APC 
3482 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
  
- 
 
 - 
 
 - 
 
 - 40 40 
Streptococcus 
agalactiae 
APC 
1055 20 20 20 320 80 80 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 20 
 
 - 
Streptococcus 
agalactiae 
ATCC 
13813 20 20 
 
 - 80 80 80 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
Streptococcus bovis 
DPC 
6491 40 40 20 40 40 80 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 320 
 
 - 
Streptococcus 
dysgalactiae 
APC 
3484 40 40 
 
 - 80 40 40 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 
Streptococcus uberis 
DPC 
5344 
 
 - 
 
 - 
 
 - 80 40 40 
 
 - 
 
 - 
 
 - 
 
 - 
 
 - 40 20 
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